


YKL-1-116



Category	Parameter	Description
Compound	Name	YKL-1-116
	Citations	"Activation of the p53 Transcriptional Program Sensitizes Cancer Cells to Cdk7 Inhibitors" <i>Cell reports</i> 21.2 (2017): 467-481. "Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13" <i>eLife</i> 2018 Nov 13; 7.
	Chemical descriptors	CC1(C)N(C(N[C@H](CN(C)C)C2=CC=CC=C2)=O)CC3=C1NN=C3NC4=CC(NC(C5=CC=C(NC(C=C)O)C=C5)=O)=CC=C4
	Chemical name	(S)-3-((3-(4-acrylamidobenzamido)phenyl)amino)-N-(2-(dimethylamino)-1-phenylethyl)-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide
	Entries in chemical databases	CID 121444083
	Availability	
<i>In vitro</i> profiling	Target (potency)	CDK7 : IC ₅₀ = 7.6 nM (Invitrogen, biochemical assay)
	Target (potency)	CDK9 : IC ₅₀ > 1 μM; CDK2 : IC ₅₀ = 1.1 μM; CHK2 : IC ₅₀ = 7.4 nM; FGR : IC ₅₀ = 5.1 nM; HIP4K : IC ₅₀ = 178 nM; PRKCC : IC ₅₀ = 4.9 nM; RET : IC ₅₀ = 63.5 nM; SRC : IC ₅₀ = 3.9 nM (Invitrogen, biochemical assay)
	Selectivity	YKL-1-116 selectivity was assessed by KiNativ profiling in Jurkat cells @ 1 μM
	Potential reactivity	Cysteine reactive
	SAR	
	Mechanism of inhibition	Irreversible
Cellular profiling	Structure of target-probe complex	N/A
	Validation of cellular target	YKL-1-116 dose-dependently targets CDK7 in HCT116, Jurkat, Kuramochi, OVCAR8, and COV362 cancer cells as assessed by intracellular target engagement
	Validation of cellular specificity	OVCAR8 cells overexpressing a CDK7 mutant lacking the requisite cysteine (Cys312) is approximately 6-fold less sensitive to YKL-1-116 (Note: C312S mutant was overexpressed via viral transduction, leaving endogenous CDK7 unchanged); selectivity was also assessed by KiNativ profiling assay in Jurkat cells @ 1 μM
	Additional comments	
Pharmacodynamics	N/A	
Pharmacokinetics	N/A	

Synthetic scheme

